Asahi Kasei (AHKSY)
(Delayed Data from OTC)
$13.67 USD
-0.06 (-0.47%)
Updated Apr 25, 2024 03:50 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AHKSY 13.67 -0.06(-0.47%)
Will AHKSY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AHKSY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AHKSY
New Strong Sell Stocks for October 12th
AHKSY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for AHKSY
Honda to build Canada's first comprehensive electric vehicle supply chain, creating thousands of new jobs in Ontario
Honda Plans to Establish Comprehensive Electric Vehicle Value Chain in Ontario, Canada
Honda planning to expand its electric vehicle efforts in Canada, Toyota expands in Indiana
Asahi Kasei to Construct a Lithium-ion Battery Separator Plant in Canada
Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development